For healthcare professionals only


NICE guidance “a real victory” for people with schizophrenia

BMJ 2002; 324 doi: (Published 15 June 2002) Cite this as: BMJ 2002;324:1413
  1. Alex Vass
  1. BMJ

    The National Institute for Clinical Excellence (NICE) has recommended the more widespread use of atypical antipsychotic drugs for patients with schizophrenia on the grounds that they have fewer side effects and are as effective as the older drugs commonly prescribed for the condition.

    Releasing its recommendations after a year long review of over 200 trials, the institute said that older antipsychotic drugs (such as chlorpromazine and haloperidol) were associated with a higher incidence of extrapyramidal side effects (such as parkinsonism, acute dystonic …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription